A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor

Tim J. Fyfe, Barbara Zarzycka, Herman D. Lim, Barrie Kellam, Shailesh N. Mistry, Vsevolod Katrich, Peter J. Scammells, J. Robert Lane, Ben Capuano

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

Original languageEnglish
Pages (from-to)174-206
Number of pages33
JournalJournal of Medicinal Chemistry
Volume62
Issue number1
DOIs
Publication statusPublished - 1 Oct 2019
Externally publishedYes

Fingerprint

Dopamine
Ligands
Dopamine Receptors
Pharmacology
thieno(2,3-d)pyrimidine

Cite this

Fyfe, Tim J. ; Zarzycka, Barbara ; Lim, Herman D. ; Kellam, Barrie ; Mistry, Shailesh N. ; Katrich, Vsevolod ; Scammells, Peter J. ; Lane, J. Robert ; Capuano, Ben. / A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor. In: Journal of Medicinal Chemistry. 2019 ; Vol. 62, No. 1. pp. 174-206.
@article{0deb065571f543a6aadac3b731fa1348,
title = "A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor",
abstract = "Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.",
author = "Fyfe, {Tim J.} and Barbara Zarzycka and Lim, {Herman D.} and Barrie Kellam and Mistry, {Shailesh N.} and Vsevolod Katrich and Scammells, {Peter J.} and Lane, {J. Robert} and Ben Capuano",
year = "2019",
month = "10",
day = "1",
doi = "10.1021/acs.jmedchem.7b01565",
language = "English",
volume = "62",
pages = "174--206",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "1",

}

Fyfe, TJ, Zarzycka, B, Lim, HD, Kellam, B, Mistry, SN, Katrich, V, Scammells, PJ, Lane, JR & Capuano, B 2019, 'A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor' Journal of Medicinal Chemistry, vol. 62, no. 1, pp. 174-206. https://doi.org/10.1021/acs.jmedchem.7b01565

A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor. / Fyfe, Tim J.; Zarzycka, Barbara; Lim, Herman D.; Kellam, Barrie; Mistry, Shailesh N.; Katrich, Vsevolod; Scammells, Peter J.; Lane, J. Robert; Capuano, Ben.

In: Journal of Medicinal Chemistry, Vol. 62, No. 1, 01.10.2019, p. 174-206.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D 2 Receptor

AU - Fyfe, Tim J.

AU - Zarzycka, Barbara

AU - Lim, Herman D.

AU - Kellam, Barrie

AU - Mistry, Shailesh N.

AU - Katrich, Vsevolod

AU - Scammells, Peter J.

AU - Lane, J. Robert

AU - Capuano, Ben

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

AB - Recently, a novel negative allosteric modulator (NAM) of the D 2 -like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

UR - http://www.scopus.com/inward/record.url?scp=85046490671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046490671&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.7b01565

DO - 10.1021/acs.jmedchem.7b01565

M3 - Article

VL - 62

SP - 174

EP - 206

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 1

ER -